The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C
Rika Iwata(University Hospital Zurich), Athanasios Vergopoulos(University Hospital Zurich), Pascal Frei(University Hospital Zurich), Stéphanie Bibert(University of Lausanne), Pierre–Yves Bochud(University of Lausanne), Beat Müllhaupt(University Hospital of Zurich), Bruno Stieger(University Hospital of Zurich), Oliver Goetze(University Hospital Zurich), Andreas Geier(Swiss Integrative Center for Human Health), Thomas Berg(Leipzig University of Applied Sciences), Joseph M. Braun(Brown University), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), I. V. Martin(University Hospital Zurich), Tobias Müller(University of Cambridge), Katharina Baur(University Hospital Zurich), Johannes Schmitt(University Hospital Zurich)
Cited by 29
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
|Annals of the Rheumatic Diseases|2011|988
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877